ADR Profile of the Covishield Vaccine among Healthcare Workers in a Tertiary Care Teaching Hospital in India

• Published in: Current drug safety
• Main Authors: Deb, Tirthankar, Garg, Rajesh, Kaur, Manmeet, Beniwal, Ankita, Gupta, Varsha
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.11.2022
• Subjects: COVID-19; ADRs; Covishield; beneficiaries; healthcare workers; vaccination
• ISSN: 2212-3911
• DOI: 10.2174/1574886317666220113101815

Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). Though many classes of drugs have been advocated/ used for the treatment of this disease, vaccines are being targeted for the ultimate prevention of this deadly disease. Indian Government has approved Covishield (ChAdOx1 nCoV19 Corona Virus Vaccine-Recombinant) for restricted use in emergency circumstances Objective. This study is aimed at evaluating the safety profile of the Covishield vaccine among healthcare workers in a tertiary care hospital. All Adverse Drug Reactions (ADRs) reported to ADR monitoring centre by healthcare workers who received the Covishield vaccine during the study period of 3 months were analysed on various parameters and the assessment was done using WHO-UMC scale. During the study period, total of 1216 beneficiaries were vaccinated with 1st dose of Covishield and out of these, 727 beneficiaries also received 2nd dose of the vaccine. Out of total 1216 beneficiaries vaccinated, 69 ADRs were reported in 24 healthcare workers. The most common ADR reported was fever (25%), followed by myalgia (19%). No death or any serious anaphylactic reaction was observed. None of the healthcare workers experienced any adverse event during the observation period of 30 minutes. Serious reactions were reported in 4 healthcare workers as per the Pharmacovigilance Programme of India (PvPI) criteria of Serious AEFI. 92% of healthcare workers recovered from ADRs during the study period. 84% of ADRs were classified as probable as per the WHO-UMC scale. As per the Government of India directives all the healthcare workers in the institute were encouraged to take both doses of the Covishield vaccine. The beneficiaries were kept under observation for 30 minutes and followed for any adverse drug reaction following vaccination. The vaccine was found to be safe with a very low incidence of ADRs.